To elucidate the clinical importance of estrogen receptor (ER) ␤ in breast cancer, 29 archival primary breast cancer specimens, six locally recurrent cancers, and five benign mammary tumors were examined histochemically for ER␣, ER␤ and the proliferation markers Ki67 and cyclin A. In benign tumors, most epithelial cells contained ER␤, but ER␣ was rare. In primary cancers, both ER␣ and ER␤ occurred in epithelial cells, the presence of ER␤ being associated with elevated expression of Ki67 and cyclin A, and ER␣ with decreased levels. Thus, the highest content of proliferation markers was seen in primary cancers that were ER␣ ؊ ER␤ ؉ . Most Ki67-containing cells coexpressed ER␤, but few showed ER␣. In locally recurring cancers, ER␣, ER␤, and Ki67 were more highly expressed than in the corresponding primary tumors, and many cells containing ER␤, but few with ER␣, expressed Ki67. Surprisingly, ER␤, but not ER␣, was seen in the stromal cells of both primary and recurrent cancers. Because the response of breast cancers to tamoxifen therapy is correlated with the presence of ER␣, cancer cells that lack ER␣ but contain ER␤ and proliferation markers represent a novel population of apparently proliferating cells that probably are not targeted by the current antiestrogens. Thus, appropriate ER␤-specific ligands, perhaps in combination with tamoxifen, may be useful in improving the treatment of breast cancers.
strogen is a modulator of cellular growth and differentiation (1) . Its major targets in females are the mammary gland and uterus, but in both males and females this hormone is essential for maintenance of bone, brain, the cardiovascular system, and the urogenital tract (2) (3) (4) . Estrogen mediates most of its functions through two specific intracellular receptors, ER␣ and ER␤ (5) , which are hormone-dependent transcription regulators.
Estrogen also is associated with the induction and growth of breast cancer. Animal studies have shown that estrogen can induce and stimulate breast cancer, and ovariectomy or administration of antiestrogens opposes this action (6) (7) (8) (9) . Because ER␣-containing epithelial cells in the normal breast do not express proliferation markers (10) (11) (12) , the mechanisms through which estrogen induces epithelial growth are not clear. The prevailing concept is that it induces the secretion of growth factors from the stroma and that these agents stimulate epithelial cells to proliferate (13) . This explanation leaves two questions: (i) why do ER␣-containing normal cells not proliferate? and (ii) do ER␣-containing cells in breast cancer epithelium proliferate in response to estrogen? There is no clear answer to the first question, but an untested possibility is that ER␣-containing cells do receive proliferation signals and proliferate but that ER␣ must be restricted for progression through the cell cycle to occur. There is evidence that ER␣ is rapidly down-regulated in cell lines in response to estradiol treatment (14, 15) .
In the rodent mammary gland, most of the cells that express the proliferating cell nuclear antigen contain neither ER␣ nor ER␤ (16) , which suggests that the presence of ERs in epithelial cells restricts their proliferation. Regulation of growth factor receptors in the breast supports this role for ER. In breast cancer cells in culture, loss of ER␣ is accompanied by an increase in growth factors and growth factor receptors (17) (18) (19) , as well as higher levels of phosphotyrosine residues indicating increased tyrosine kinase activity (20) .
Expression of ER␤ mRNAs has been detected by reverse transcriptase-PCR in both normal and malignant human breast tissue (21) , and full-length ER␤ protein (ER␤1) has been identified in human breast tumors by Western blotting (22) .
Immunohistochemistry of breast cancer tissue shows that ER␤ is often coexpressed with ER␣ and that the presence of this receptor is associated with negative axillary node status and low tumor grade (23) . Although it has been suggested that ER␤ contributes to the initiation and progression of carcinogenesis (24) , is expressed in breast cancers of higher grades (21) , and is a marker for estrogen responsiveness (25) , its precise role in breast tissue remains to be defined.
Clinical studies show that beneficial response of breast cancer to tamoxifen (26) , as well as to other endocrine therapies (27) , is related to the presence of ER␣. Furthermore, breast cancer prevention trials show that there is a reduced incidence of ER␣-positive but not ER␣-negative cancers in the tamoxifentreated group (28) . Because ER␤ is present in breast tumors, it is pertinent to ask whether proliferation and͞or survival of ER␤-expressing cells are affected by tamoxifen. To provide insight into this question, we have examined the cellular distribution of the two ERs in mammary neoplasms and investigated the relationship between cell proliferation markers and ER expression pattern.
Materials and Methods
Tissue Collection. Paraffin-embedded breast tumor sections from 34 patients undergoing breast cancer surgery were provided by the Helsinki University Central Hospital and the Charing Cross Hospital, London. They were composed of 25 invasive ductal cancers, four lobular cancers, and five benign mammary tumors. Information was recorded concerning the patient's age and menopausal status, the pathological diagnosis and differentiation grade of the tumor, and ER␣ positivity as determined immunohistochemically. Of the 29 cancer patients, six developed local recurrence during or after adjuvant tamoxifen treatment for 1-5 years, and sections of the recurrent cancers were compared with those from the primary tumors.
human ER␤ polyclonal (06-629) was from Upstate Biotechnology (Lake Placid, NY); Ki67 monoclonal (Mib-1, M7240) and Ki67 rabbit polyclonal (A0047) were from Dako, and cyclin A rabbit polyclonal (H432) was from Santa Cruz Biotechnology. Biotinylated secondary antibodies (goat anti-mouse IgG and goat anti-rabbit IgG) and avidin-biotin kits were obtained from Vector Laboratories. FITC-conjugated anti-rabbit and Cy3-conjugated anti-mouse antibodies were from Jackson ImmunoResearch.
Immunohistochemistry. Paraffin sections (4 m) were dewaxed in xylene and rehydrated through graduated ethanol to water. Endogenous peroxidase was blocked by incubation for 30 min with a solution of 1% hydrogen peroxide, and antigen retrieval was performed by microwaving sections in 0.01 M citrate buffer, pH 6.0, for 20 min at 800 W.
Single Antibody Immunostaining. Tissue sections were incubated for 1 h at 4°C with normal goat serum diluted at 1͞10 in PBS. Antibodies were diluted individually in PBS containing 3% BSA. Dilution was 1:100 for ER␤, Ki67, and cyclin A antibodies and 1:500 for ER␣ antibody. Sections were incubated with antibodies overnight at 4°C. For negative controls, the primary antibody was replaced with PBS alone or with primary antibody after absorption with the corresponding antigen. Before addition of secondary antibody, sections were rinsed in PBS containing 0.05% Tween 20. The ABC method was used to visualize the signal according to the manual provided by the Fig. 1 . Expression of ER␣, ER␤, Ki67, and cyclin A in breast fibroadenoma and invasive ductal cancer. In fibroadenomas, ER␣ is seen only in epithelial cells (A), whereas ER␤ is expressed in both epithelium and stroma (B). There was little Ki67 or cyclin A expression (C and D). In invasive ductal cancers, four patterns of ER expression can be identified: ER␣ ϩ ER␤ ϩ (E and F), ER␣ ϩ ER␤ Ϫ (I and J), ER␣ Ϫ ER␤ ϩ (M and N), and ER␣ Ϫ ER␤ Ϫ (Q and R). Some Ki67-and cyclin A-containing cells appear in ER␣ ϩ ER␤ ϩ specimens (G and H), but ER␣ Ϫ ER␤ ϩ cancers express much higher levels of these proliferation markers (O and P). In contrast, ER␣ ϩ ER␤ Ϫ and ER␣ Ϫ ER␤ Ϫ tumors contain little Ki67 or cyclin A (K, L, S, and T). (Magnification: ϫ200.) manufacturer (Vector Laboratories). Sections were incubated in biotinylated goat anti-rabbit or goat anti-mouse Ig (1:200 dilution) for 2 h at room temperature, followed by washing with PBS and incubation in avidin-biotin-horseradish peroxidase for 1 h. After thorough washing in PBS, sections were developed with 3,3Ј-diaminobenzidine tetra-hydrochloride (Dako), slightly counterstained with Mayers hematoxylin, and dehydrated through an ethanol series, followed by exposure to xylene and mounting.
The percentage of positively stained cells is an average after counting the stained and the total number of cells from four high-magnification fields with the software IMAGE-PRO PLUS 4.1 (Media Cybernetics, Silver Spring, MD). Double Antibody Immunostaining. Tissue sections were incubated for 1 h at 4°C with normal donkey serum (Sigma) diluted 1:10 in antibody diluent. This was followed by an overnight incubation at 4°C with a mixture composed of antibodies to either ER␣ and ER␤, ER␣ and Ki67 (A0047), or ER␤ and Ki67 (M7240). PBS alone was used in place of these mixtures in the negative controls. Before addition of secondary antibodies, sections were washed with PBS containing 0.05% Tween 20. Slides were incubated for 1 h with a mixture of FITC-conjugated donkey anti-rabbit (1:100) and Cy3-conjugated donkey anti-mouse (1:200) antibody. After washing with PBS for 30 min, the slides were incubated with 0.1 g͞ml of 4Ј,6-diamidino-2-phenylindole dihydrochloride in PBS for 30 s, washed three times in PBS, and mounted with Vectashield.
Statistical Analysis. Statistical differences between groups were analyzed with Student's t test and ANOVA using SPSS (SPSS, Chicago). A value of P Ͻ 0.05 was considered significant.
Results
Single Antibody Staining. The expression of ER␣, ER␤, Ki67, and cyclin A was analyzed in paraffin sections of 29 invasive breast cancers and five benign tumors (Fig. 1) . Specimens in which no positively stained cells were detected were taken as ER␣ Ϫ or ER␤ Ϫ . In receptor-positive specimens, the abundance of cells containing ER␣ or ER␤ varied from 33% to 86%. Ki67 and cyclin A were expressed in all samples, but the percentage of positive cells per section varied widely from 0.1% to 34%. Staining for ER␣ in this study was in agreement with ER␣ analyses done at the time of initial surgery.
Of the benign tumors, two fibroadenomas and one papilloma expressed both ER␣ and ER␤, with ER␤-positive cells being more abundant than ER␣-positive. In one papilloma neither ER␣ nor ER␤ was detectable. In fibroadenomas, there were few ER␣-positive cells and these were exclusively epithelial (Fig. 1 A) , whereas ER␤-positive cells were abundant in both epithelium and stroma (Fig. 1B) . Ki67 and cyclin A were present in less than 0.1% of the cells in all five benign tumors ( Fig. 1 C and D) .
In the 29 invasive cancers, 18 (62%) contained ER␣ and 19 (65%) ER␤ (Table 1 ). In ER␣ ϩ cancers, Ki67 and cyclin A were expressed in 5% and 2% of the cells, respectively, whereas in ER␣ Ϫ cancers, the values were 17% and 12% (P Ͻ 0.05). In contrast to ER␣, the expression of ER␤ was associated with a higher content of Ki67 and cyclin A. The percentages of Ki67-and cyclin A-positive cells in ER␤ ϩ cancers were 13% and 8%, respectively, significantly higher than the corresponding values of 2% and 1% seen in ER␤ Ϫ cancers (P Ͻ 0.05).
There were four patterns of ER expression in the epithelium of the 29 breast cancer samples, and these patterns occurred with different frequency. (Fig. 1) .
Although the expression of ER␣ and ER␤ bore no relationship to differentiation grade (P Ͼ 0.05), Ki67 and cyclin A were more prevalent in cancers of higher grade. In cancers of grade 3, the average percentage of cells expressing Ki67 and cyclin A was 28% and 21%, respectively, as compared with 9% and 7% in grade 2, and 7% and 3% in grade 1 (P Ͻ 0.01). In cancers from the nine node-positive patients, 19% of the cells showed staining for Ki67 and 15% for cyclin A. This is a higher expression than that seen with the 14 node-negative patients, where the corresponding values were 8% and 5%, respectively (P Ͻ 0.05).
Coexpression of ERs with Ki67.
To determine whether ERs are expressed in proliferating cells, individual tumor sections were exposed to the following combinations of antibodies raised against the proteins indicated: ER␣ and ER␤; ER␣ and Ki67 (A0047); and ER␤ and Ki67 (M7240). As shown in Fig. 2 , in ER␣ ϩ ER␤ ϩ cancers, all of the ER␣-containing cells also expressed ER␤ (Fig. 2 A-C) . In ER␣ ϩ ER␤ ϩ and ER␣ ϩ ER␤ Ϫ cancers, some cells expressed Ki67, but in very few instances was this proliferation marker present in the same cells that contained ER␣ (Fig. 2 D-F) . In specimens where ER␤ was much more abundant than ER␣, there were many Ki67-positive cells, 98% of which expressed ER␤ (Fig. 2 G-I ).
ERs and Ki67 in Recurrent Cancers. After initial breast cancer surgery, the patients received adjuvant tamoxifen therapy for 1-5 years. Six patients who had local recurrence were selected for study. In three of the patients, local breast cancer recurred during the tamoxifen treatment, whereas three other patients had recurrence 2, 8, and 9 years after cessation of tamoxifen therapy. ER␣ was expressed in all of the primary and recurrent tumors, whereas ER␤ was present in four primary cancer specimens but in all six of the recurrent tumors. Thus the recurrent cancers were all ER␣ Primary and recurrent cancer specimens from individual patients were compared to determine whether there were changes in the populations of cells showing colocalization of ER␣ and ER␤, ER␣ and Ki67, and ER␤ and Ki67. Although the contents of ER␣ and Ki67 were higher in recurrent (Fig. 3 D and E) than in primary cancers ( Fig. 3 A and B) , coexpression with ER␣ was seen in less than 5% of the Ki67 ϩ cells (Fig. 3 C and  F, arrow) . However, in both primary (Fig. 3 G-I ) and recurrent specimens (Fig. 3 J-L) , 70-85% of the Ki67 ϩ cells expressed ER␤ whereas 15-29% did not contain either ER (Fig. 3 I and L,  red) .
Discussion
The most striking findings of this study of ER␣ and ER␤ in breast neoplasms are: (i) The presence of ER␣ in breast cancer epithelium is associated with a decreased expression of the proliferation markers, Ki67 and cyclin A, whereas ER␤ expression is associated with elevated levels of these markers. The highest expression of either Ki67 or cyclin A is seen in cancers that are ER␣
(ii) The only ER in the stroma of breast tumors is ER␤, whereas both ER␣ and ER␤ are present in the epithelial cells. (iii) Both ER␣ and ER␤ are expressed in recurrent breast cancers at higher levels than those in the corresponding primaries. (iv) In recurrent breast cancers, the presence of ER␣ is not associated with a lower levels of Ki67, as it is in primary cancers.
The presence of ER␣ in breast cancers is generally taken as an indication of hormone dependency (27) , and, on this basis, treatment with antiestrogen (tamoxifen) is now the first-line therapy, both for metastatic disease and as adjuvant therapy after mastectomy (29, 30) . Despite the initial benefits of tamoxifen, most patients eventually relapse with tumors that not only are tamoxifen-resistant but actually are stimulated by this agent (31) .
In this study, we found that very few ER␣-containing cells express proliferation markers and that cancers that are ER␣ cancers, proliferation markers are the lowest regardless of whether or not they contain ER␣. These results suggest that it might be ER␤, and not ER␣, that is related to proliferation in breast cancer.
In the recurrent cancers, the expression of ER␣, ER␤, and Ki67 was higher than that seen in the primary cancers from the same patients. All recurrence specimens were ER␣ ϩ ER␤ ϩ , with a level of Ki67 that was higher than that in ER␣ ϩ ER␤ ϩ primary cancers. In both primary and recurrence specimens, less than 5% of the ER␣ ϩ cells expressed Ki67, but most of the Ki67-containing cells expressed ER␤.
It is known that only two-thirds of the patients with ER␣-positive breast cancers respond to tamoxifen and that very few patients, classified as ER␣-negative, benefit from tamoxifen therapy (29, 30) . Clinically, ER␣ is measured either by estradiol binding, which detects both ER␣ and ER␤, and immunoassay, which detects only ER␣. Because there is a clear relationship between response to tamoxifen and ER␣ content of the tumor, it may be that ER␤-positive, proliferating cells are insensitive to tamoxifen. Such cells may even depend on tamoxifen for growth, because it is known that ER␤ in the presence of tamoxifen activates AP-1 response elements (32, 33) . Other recent studies have suggested that ER␤ is a prognostic marker in breast cancer, particularly for identifying tumors resistant to tamoxifen (23, 34, 35) .
The beneficial effect of tamoxifen in breast cancer is probably caused by its effect on ER␣-positive cells, very few of which are proliferating. Antagonism of ER␣ in these cells may result in reduction of the tumor burden and͞or the removal of growth factors, which may be proliferative signals for ER␤-containing cells. Because the ER␤-containing, proliferating cells in the tumor probably are not targets of tamoxifen, addition of an ER␤ antagonist to the therapeutic regimen may be useful in the clinical management of both primary and advanced breast cancers, particularly those that are stimulated by tamoxifen.
An unexpected finding in this study is that ER␤ was the only ER detected in breast cancer stroma. The lack of ER␣ in human breast stroma has been observed previously (36) . In rodents, ER␣ is present in the breast stroma and is responsible for secretion of growth factors (epithelial cellular mitogens) in response to estradiol. Tissue recombinants with stroma and epithelium from normal as compared to ER␣ knockout mice have demonstrated that ER␣ in the stroma is responsible for estrogen-induced epithelial growth in response to estradiol (37) . Whether the distribution of ERs in different cellular compartments of breast tissue is different in rodents than in humans or whether there are variations between individual patients that have not been addressed in our specimens, are questions that need further examination.
From the foregoing data, it appears that to obtain a more complete picture of the action of antiestrogens in breast cancer therapy, both ER␣ and ER␤ should be measured in the tumor. Although the number of patients is relatively small, from this limited study it is evident that the expression of ER␤ is important in cell proliferation in breast cancers and, possibly, in their response to tamoxifen.
